Differential inhibitory effects of phenytoin, diclofenac, phenylbutazone and a series of sulfonam ides on hepatic cytochrom e P4502C activity in vitro, and correlation with som e m olecular descriptors in the dwarf goat (Caprus hircus aegagrus).

References

• BACK, D. J., TJIA, J. F., KARBWANG, J. and COLBERT, J., 1988, In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. British Journal of Clinical Pharmacology, 26, 23–29.
   PubMed Web of Science ®Google Scholar
• BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARKE, S. E. and CITENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotka, 25(3), 261–170.
   PubMed Web of Science ®Google Scholar
• BELANGER, P. M. and ST-HILAIRE, S., 1991, The characteristics of the microsomal hydroxylation of tolbutamide. Canadian Journal of Physiology and Pharmacology, 69, 400–405.
   Google Scholar
• BRIAN, W. R., SRIVASTAVA, P. K., UMBENHAUER, D. R., LLOYD, R. S. and GUENGERICH, F. P., 1989, Expression of a human liver cytochrome P450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry, 28, 4993–4999.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN, I. K., HANSEN, J. M. and KRISTENSEN, M., 1963, Sulphaphenazole-induced hypo-glycaemic attacks in tolbutamide-treated diabetics. Lancet, ii, 1298.
   Google Scholar
• DENIZAT, F. and LANG, R., 1986, Rapid colorimetric assay for cell growth and survival. Journal of Immunological Methods, 89, 271–277.
   PubMed Web of Science ®Google Scholar
• DEWAR, M. J. S., ZOEBISCH, E. G., HEALY, E. F. and ST'EWART, J. J. P., 1985, Journal of the American Chemistry Society, 107, 3902–3909.
   Google Scholar
• DOECKE, C. J., VERONESE M. E., POND, S. M., MINERS, J. 0., BIRICETT D. J., SANSOM, L. N. and McMANus, M. E., 1991, Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. British Journal of Clinical Pharmacology, 31, 125–130.
   Google Scholar
• GOLDSTEIN, J. A. and MORAIS, S. M. F., 1994, Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics, 4, 285–299.
   PubMedGoogle Scholar
• GONZALEZ, F. J., 1992, Human cytochrome P450: problems and prospects. Trends in Pharmacological Science, 13, 346–352.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., 1989, Characterization of human microsomal cytochrome P450 enzymes. Annual Reviews in Pharmacology and Toxicology, 29, 241–264.
   PubMed Web of Science ®Google Scholar
• GUENGERICH, F. P., MULLER -ENOCH D. and BLAIR, I. A., 1986, Oxidation of quinidine by human liver cytochrome P-450. Molecular Pharmacology, 30, 311–316.
   Google Scholar
• HEHRE, W. J., BURKE, L. D. and SHUSTERMAN, A. J., 1993, SpartanUser's Guide (Irvine: Wavefunction). LEEMANN, T. D., TANSON, C. and DAYER, P., 1993, Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. Life Sciences, 52, 29–34. LEO, D. and WEININGER, D., 1989, MedCem Software Manual v Software (Irvine: Daylight Chimical Information Systems).
   Google Scholar
• LOWRY, 0. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265–275.
   Google Scholar
• MINERS, J. 0., SMITH, K. J., ROBSON, R. A., McMANus, M. E., VERONESE M. E. and BIRKETT, D. J., 1988, Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochemical Phar-macology, 37 (6), 1137–1144.
   Google Scholar
• NELSON, D. R., KOYMANS, L., KAMATAKI, T., STEGEMAN J. J., FEYEREISEN, R., WAXMAN, P. J., WATERmAN, M. R., GOTOH 0., COON, M. J., ESTABROOK, R. W., GUNSALUS, I. C. and NEBERT D. W., 1996, P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature, Pharmacogenetics, 6, 1–42.
   Google Scholar
• NEWLANDS, A. J., SMITH, D. A., Jos, B. C. and HAWKSWORTH, G. M., 1992, Metabolism of nonsteroidal anti-inflammatory drugs by cytochrome P450-2C. British Journal of Clinical Pharmacology, 34, 160P.
   Google Scholar
• PURBA, H. S., BACK, D. J. and ORE, M. L. E., 1987, Tolbutamide-4-hydroxylase activity of human liver microsomes: effect of inhibitors. British Journal of Clinical Pharmacology, 24, 230–234.
   PubMed Web of Science ®Google Scholar
• RELLING, M. V., AOYAMA, T., GONZALES, F. J. and MEYER, U. A., 1990, Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. Journal of Pharmacology and Experimental Therapeutics, 31, 125–130.
   Google Scholar
• RETTIE, A. E., KORZEKWA, K. R., KUNZE, K. L., LAWRENCE, R. F., EDDY, A. C., AOYAMA, T., GELBOIN H. V., GONZALES, F. J. and TRAGER, W. F., 1992, Hydroxylation of warfarin by human cDNA-expressed cytochrome P450: a role for P4502C9 in the etiology of (S)-warfarin drug interactions. Chemical Research in Toxicology, 5, 54–59.
   Google Scholar
• RUTTEN, A. A. J. J. L., FALKE, H. E., CATSBURG, J. F., TOPP, R., BLAAUBOER, B. J., HOSTEYN VAN, I., DOORN, L. and LEEUWEN VAN, F. X. R., 1987, Inter-laboratory comparison of total cytochrome P450 and protein determinations in rat liver microsomes. Archives of Toxicology, 61, 27–33.
   Google Scholar
• SIERSBAEK -NIELSEN, K., HANSEN, J. M., SKOWSTED, L., LUMHOLTZ, B. and KAMP MANN, J., 1973, Sulphamethizole-induced inhibition of diphenyldantoin and tolbutamide metabolism in man. Clinical Pharmacology and Therapeutics, 14, 148.
   Google Scholar
• SEGLEN, P. 0., 1976, Preparation of isolated rat liver cells. Methods in Cell Biology, 13, 29–83. SOELDNER, J. A. and STEINICE, J., 1965, Hypoglyceamia in tolbutamide-treated diabetis. Journal of the American Medical Association, 193, 148.
   Google Scholar
• THIESSEN, J. J. and ROWLAND, M., 1977, Kinetics of drug-drug interactions in sheep: tolbutamide and sulfadimethoxine. Journal of Pharmaceutical Sciences, 66(8), 1063–1070.
   PubMed Web of Science ®Google Scholar
• TRACY, T. S., ROSENBLUTH, B. W., WRIGHTON, S. A., GoNzALEs, F. J. and KORZEKWA, K. R., 1995, Role of cytochrome P4502C9 and an allelic variant in the 4'-hydroxylation of (R)- and (S)-flurbiprofen. Biochemical Pharmacology, 49, 1269–1275.
   PubMed Web of Science ®Google Scholar
• VERHAAR, H. J. M., URRESTARAZU RAMOS, E. and HERMENS, J. L. M., 1996, Classifying environmental pollutants. 2: Separation of class 1 (baseline toxicity) and class 2 ('polar narcosis') type compounds based on chemical descriptors. journal of Chemometrics, 10, 149–162.
   Google Scholar
• VERONESE, M. E., McMANus, M. E., LAUPATTARAKASEM, P., MINERS, J. 0. and BIRKETT, D. J., 1990, Tolbutamide hydroxylation by human, rabbit and rat liver microsomes and by purified forms of cytochrome P450. Drug Metabolism and Disposition, 18(3), 356–361.
   Google Scholar
• VERONESE M. E., MACKENZIE, P. E., DOECKE, C. J., MCMANUS, M. E., MINERS, J. 0. and BIRKETT D. J., 1991, Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cyto-chrome P4502C9. Biochemical and Biophysical Research Communications, 175(3), 1112–1118.
   Google Scholar
• ZHAO, J., LEEMANN, T. and DAYER, P., 1992, In vitro oxidation of oxicam NSAIDs by a human liver cytochrome P450. Life Sciences, 51(8), 575–581.
   PubMed Web of Science ®Google Scholar
• ZWEERS -ZEILMAKER W. M., BATZIAS, J., Ms, R. F. M., HORBACH, G. J., MIERT VAN, A. S. J. P. A. M. and WITICAMP, R. F., 1996, In vitro and in vivo oxidative biotransformation in the dwarf goat. Substrate activities and effects of inducers. Xenobiotka, 26(11), 1131–1141.
   PubMed Web of Science ®Google Scholar